Tom Strange
Private Equity Investor bij iCON Infrastructure LLP
Actieve functies van Tom Strange
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
iCON Infrastructure LLP
 iCON Infrastructure LLP Investment ManagersFinance iCON Infrastructure LLP is a private equity firm founded in 2004 by Paul Malan. The firm is headquartered in London, United Kingdom with offices in Germany, Canada and the United States. | Private Equity Investor | 01-06-2023 | - |
Loopbaan van Tom Strange
Eerdere bekende functies van Tom Strange
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
MiroBio Ltd.
 MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Private Equity Investor | 01-04-2022 | 01-11-2022 |
Opleiding van Tom Strange
| University of Cambridge | Graduate Degree |
| The University of Nottingham | Undergraduate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 4 |
| Verenigde Staten | 2 |
Operationeel
| Private Equity Investor | 2 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
iCON Infrastructure LLP
iCON Infrastructure LLP Investment ManagersFinance iCON Infrastructure LLP is a private equity firm founded in 2004 by Paul Malan. The firm is headquartered in London, United Kingdom with offices in Germany, Canada and the United States. | Finance |
MiroBio Ltd.
MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Tom Strange
- Ervaring
